Porton Advanced Solutions and EVA Pharma have signed a Memorandum of Understanding (MOU) to enhance the development and manufacturing capabilities of chimeric antigen receptor (CAR) T cell therapies in the latter facility.
The collaboration will establish a platform for the treatment of leukemia and other blood cancers in the Middle East and Africa (MEA).
Under the MoU, both companies will focus on advancing the development and mass production of lentiviral vectors, which is crucial for automotive T cell therapies used to treat leukemia and other cancers.
Porton Advanced will apply its knowledge in viral vector technology and the development of CAR-T cell therapy processes to enhance EVA Pharma's mission to provide safe, effective and scalable cancer treatments.
“The patients who fight cancer deserve more; once they are out of reach, they should be innovative.
“Together, Eva Pharma and Porton Advanced combine our capabilities with scale and equity.”
The collaboration will combine Porton Advanced’s ability to manufacture viral vectors and cell therapies with EVA Pharma’s expanded presence in the high-tech biopharmaceutical field.
In addition, EVA Pharma also brings MEA's infrastructure and market position.
The joint efforts are expected to promote technology transfer and strengthen local manufacturing capabilities for cancer treatments while adhering to strict quality standards.
“This collaboration is in line with our vision to support cutting-edge therapies that are visited globally and further validates the unique value of Porton Advanced in promoting advanced therapeutic pipelines around the world,” said Andrew Chen, Porton Advanced CFO.
The agreement is in line with international initiatives to enhance access to advanced immunotherapy, especially in areas lacking cellular and gene therapy infrastructure.
By creating local production facilities in Saudi Arabia and Egypt, the cooperation aims to reduce spending and speed up treatment time.
“Porton Advanced and Eva Pharma Collaboration for Automotive T-Cell Therapy” was originally created and published by GlobalData-owned brand Pharmaceutical Technology.
The information on this website is included in sincerity only for general information purposes. It is not intended to rely on the advice you should rely on, and we do not provide any representation, warranty or warranty that express or imply its accuracy or completeness. You must take or avoid any action based on the content on our website to obtain professional or professional advice.
